Journal of dermatological science · 2026
Imaging-guided tape stripping reveals consistent stratum corneum profiling of disease severity and treatment-responsive molecular features in pediatric atopic dermatitis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Andersen Daniel, Yélamos Oriol, Combalia Marc, Iglesias Pablo, Potrony Miriam, Danneskiold-Samsøe Niels B, Kristiansen Karsten, Thysen Anna H, Guy Richard H, Malvehy Josep, Røpke Mads, Pont Mercè, Puig Susana, Brix Susanne
Аннотация
BACKGROUND: Atopic dermatitis (AD) is a common pediatric skin disorder with early onset and complex pathophysiology. Tape-strip sampling has enabled minimally invasive molecular profiling of skin lesions in children, yet approaches that verify and standardize stratum corneum (SC) sampling depth have remained limited.
OBJECTIVE: To evaluate the utility of imaging-guided tape stripping of SC, combined with transcriptomic and cytokine profiling, for characterizing molecular changes associated with disease severity and treatment response in pediatric AD.
METHODS: By coupling real-time imaging-guided tape stripping with RNA sequencing and cytokine profiling, we examined SC molecular signatures in healthy children (n = 15) and lesional and non-lesional skin of pediatric AD patients (n = 39) with heterogeneous disease severity, both at baseline and following 2 weeks of topical corticosteroid treatment.
RESULTS: Using imaging-verified SC sampling, we identified robust molecular signatures, including > 1100 differentially expressed genes (DEGs) between healthy and AD skin, and 144 DEGs between lesional and non-lesional AD skin (fold-change ≥2, FDR <0.1). Lesional skin showed enrichment of type 17- and type 2-associated immune pathways, tissue remodeling, and cell cycle control. Thirteen transcripts were significantly associated with clinical severity or itch, including CXCL8/IL8, CD300A, and FPR1. Most of these transcripts decreased after corticosteroid treatment, whereas CD300A and FCGR2B/CD32 remained elevated in a subset of children.
CONCLUSION: These findings support the use of real-time imaging-guided tape stripping as a standardized, minimally invasive approach for verifying SC sampling depth and monitoring molecular changes associated with disease activity and treatment response in pediatric AD.
OBJECTIVE: To evaluate the utility of imaging-guided tape stripping of SC, combined with transcriptomic and cytokine profiling, for characterizing molecular changes associated with disease severity and treatment response in pediatric AD.
METHODS: By coupling real-time imaging-guided tape stripping with RNA sequencing and cytokine profiling, we examined SC molecular signatures in healthy children (n = 15) and lesional and non-lesional skin of pediatric AD patients (n = 39) with heterogeneous disease severity, both at baseline and following 2 weeks of topical corticosteroid treatment.
RESULTS: Using imaging-verified SC sampling, we identified robust molecular signatures, including > 1100 differentially expressed genes (DEGs) between healthy and AD skin, and 144 DEGs between lesional and non-lesional AD skin (fold-change ≥2, FDR <0.1). Lesional skin showed enrichment of type 17- and type 2-associated immune pathways, tissue remodeling, and cell cycle control. Thirteen transcripts were significantly associated with clinical severity or itch, including CXCL8/IL8, CD300A, and FPR1. Most of these transcripts decreased after corticosteroid treatment, whereas CD300A and FCGR2B/CD32 remained elevated in a subset of children.
CONCLUSION: These findings support the use of real-time imaging-guided tape stripping as a standardized, minimally invasive approach for verifying SC sampling depth and monitoring molecular changes associated with disease activity and treatment response in pediatric AD.